CA
SUPN icon

Claris Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Claris Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$31 – 1015
2024
Q3 		$31 Buy
+1
New +$31 ﹤0.01% 1215

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Claris Advisors's SUPN Position: Q4 2024 in Review

Claris Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q4 2024, closing a stake of 1 share — an estimated $31 sold.

Claris Advisors first reported a position in SUPN in Q3 2024 and held it in 1 quarter. The position peaked at $31 in Q3 2024. 294 funds tracked by Wall St. Rank hold SUPN as of Q4 2024.

  • Claris Advisors reported no remaining Supernus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Claris Advisors sold 1 Supernus Pharmaceuticals share in Q4 2024, an estimated $31.
  • Claris Advisors first reported a position in Supernus Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Claris Advisors's Supernus Pharmaceuticals position peaked at $31 in Q3 2024.
  • 294 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.